Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
See detail„Das Phantastische ist nur eine Dimension des Wirklichen“ [Erika Tunner]
Pontzen, Alexandra ULg

in Jean-Marie Paul, Jean-Marie (Ed.) Dimensionen des Phantastischen . Studien zu E.T.A. Hoffmann. (1998)

Detailed reference viewed: 18 (0 ULg)
See detail„Das Phantastische und das Groteske. Zu ihrem Zusammenwirken in E.T.A. Hoffmanns Nachtstücken“. [Dominique Iehl]
Pontzen, Alexandra ULg

in Paul, Jean-Marie (Ed.) Dimensionen des Phantastischen . Studien zu E.T.A. Hoffmann (1998)

Detailed reference viewed: 33 (0 ULg)
Full Text
Peer Reviewed
See detailPhantom program analysis to assess the variability in PET image quantification between different PET-CT centres
Guiot, Thomas; Vanderlinden, Bruno; Wimana, Zéna et al

in European Journal of Nuclear Medicine and Molecular Imaging (2011, October), 38(S2), 172

Detailed reference viewed: 74 (2 ULg)
See detailLes pharaons étaient adorés comme des dieux
Laboury, Dimitri ULg

in Le Grand Livre des idées reçues. Pour démêler le vrai du faux. Édition 2010 (2009)

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailPharma clinics le medicament du mois. L'esomeprazole
Louis, Edouard ULg

in Revue Médicale de Liège (2002), 57(9), 610-2

Esomeprazole is the last PPI registered on the Belgian market. It is the stable s-isomer of omeprazole. It has a better pharmacokinetic profile than omeprazole (racemate), allowing also better clinical ... [more ▼]

Esomeprazole is the last PPI registered on the Belgian market. It is the stable s-isomer of omeprazole. It has a better pharmacokinetic profile than omeprazole (racemate), allowing also better clinical performances. Esomeprazole is the first PPI shown superior to omeprazole in acute and chronic treatment of gastro-esophageal reflux disease. Controlled trials with this drug have also allowed to define new cost-effective strategies, such as on demand treatment for endoscopy-negative gastro-esophageal reflux and one week treatment of Helicobacter pylori positive duodenal ulcer. [less ▲]

Detailed reference viewed: 59 (1 ULg)
Peer Reviewed
See detailPharma clinics le medicament du mois. Le nebivolol (Nobiten).
Scheen, André ULg

in Revue Médicale de Liège (2001), 56(11), 788-91

Nebivolol (Nobiten, Menarini) is a new beta-blocker recommended for the management of essential hypertension, at a dose of 5 mg once daily. It is administered as a racemic mixture of equal proportions of ... [more ▼]

Nebivolol (Nobiten, Menarini) is a new beta-blocker recommended for the management of essential hypertension, at a dose of 5 mg once daily. It is administered as a racemic mixture of equal proportions of d- and l-enantiomers. As a lipophilic agent, it is metabolised in the liver and transformed in several active metabolites, essentially via the CYP 2D6, an isoform of cytochrome P450 characterized by a genetic polymorphism. Nebivolol is highly specific for beta-1 adrenergic receptors; it is devoid of intrinsic sympathomimetic or membrane stabilising activity. Interestingly enough, it appears to have nitric oxide-mediated vasodilatory effects which might explain its favourable haemodynamic profile. Several comparative trials demonstrated an antihypertensive activity that was similar or slightly superior to that observed with various other reference antihypertensive agents. Nebivolol has an additive antihypertensive effect in combination with hydrochlorothiazide. All studies reported that the drug has a good clinical and biological tolerance profile. Therefore, nebivolol may be recommended as an alternative first-line treatment option for the management of patients with mild to moderate essential hypertension. [less ▲]

Detailed reference viewed: 250 (1 ULg)
Full Text
Peer Reviewed
See detailPharma clinics. Comment je traite ... la sténose d'artère rénale
Krzesinski, Jean-Marie ULg; Turatzinze, Léopold

in Revue Médicale de Liège (1999), 54(9), 719-721

Renal artery stenosis is mainly due to atherosclerosis, but also to fibromuscular dysplasia. Treatment can consist eisther of angioplasty (± stent) or of surgical revascularization. Hypertension induced ... [more ▼]

Renal artery stenosis is mainly due to atherosclerosis, but also to fibromuscular dysplasia. Treatment can consist eisther of angioplasty (± stent) or of surgical revascularization. Hypertension induced by atherosclerotic disease is rarely cured, but more easily controlled. The renal function is often improved and thus this disease must be searched in the presence of renal insufficiency of unknown cause or refractory hypertension. [less ▲]

Detailed reference viewed: 32 (1 ULg)
Peer Reviewed
See detailPharma clinics. Comment je préviens et je traite ... les ulcères de stress
Fraipont, V.; Lambermont, Bernard ULg; Gast, Pierrette ULg et al

in Revue Médicale de Liège (1998), 53(8), 444-9

Stress related ulcers are superficial and extensive gastric mucosal lesions. They occur in almost all critically ill patients but lead to gastrointestinal bleedings in only 5 to 10%. Endoscopy permits ... [more ▼]

Stress related ulcers are superficial and extensive gastric mucosal lesions. They occur in almost all critically ill patients but lead to gastrointestinal bleedings in only 5 to 10%. Endoscopy permits definitive diagnostic. Stress related mucosal diseases encount for substantial morbidity and mortality. The preventive therapeutic choice depends on efficacy, side effects as cost and nosocomial pneumonia. Sulcralfate appears to be the best choice because of its lower cost, comparable efficacy (sucralfate versus anti-H2) and its lower risk of inducing nosocomial pneumonia. Patients who greatly benefit from prevention, present respiratory failure with at least 48 hours mechanical ventilation, coagulopathy, sepsis or burns. Global management avoiding hypoxia, hypotension and acidosis, takes an important part in the prevention. [less ▲]

Detailed reference viewed: 30 (1 ULg)
Full Text
Peer Reviewed
See detailPharma clinics. Comment je traite ... les troubles de la calcémie
Janssens, Lise; Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (1999), 54(10), 782-785

Treatment of both hypercalcemia and hypocalcemia depends on the underlying disorder, the magnitude of the calcium abnormalities and the severity of symptoms. In the case of hypercalcemia, there is a broad ... [more ▼]

Treatment of both hypercalcemia and hypocalcemia depends on the underlying disorder, the magnitude of the calcium abnormalities and the severity of symptoms. In the case of hypercalcemia, there is a broad selection of effective medications, especially the biphosphonates. Treatment of hypocalcemia relies on the calcium intake and often vitamin D supplementation. For both abnormalities, the underlying cause must be treated, if possible, to definitively restore normocalcemia. [less ▲]

Detailed reference viewed: 196 (12 ULg)
Full Text
See detailPharma clinics. Comment je traite ... ou préviens une douleur par "patches"
Pierard, Gérald ULg

in Revue Médicale de Liège (1998), 53(10), 586-7

There exists two distinct types of patches aiming at increasing the pain threshold either systematically or locally. The first type of analgesic patch is a real transdermal delivery system releasing ... [more ▼]

There exists two distinct types of patches aiming at increasing the pain threshold either systematically or locally. The first type of analgesic patch is a real transdermal delivery system releasing fentanyl. Such potent opioid drug exerts a systemic effect. The other type of patch associates lidocain and prilocain to induce a local anesthesia of the skin without inducing a systemic effect. [less ▲]

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailPharma clinics. Comment je traite ... un herpes labial récurrent.
Petit, L.; Braham, C.; Nikkels, Arjen ULg et al

in Revue Médicale de Liège (2002), 57(2), 67-71

Recurrent herpes labialis is a frequent disorder. It occurs following the reactivation of the Herpesvirus (HSV1 and more rarely HSV2) inside the Gasser ganglion. Treatment and prevention of recurrent ... [more ▼]

Recurrent herpes labialis is a frequent disorder. It occurs following the reactivation of the Herpesvirus (HSV1 and more rarely HSV2) inside the Gasser ganglion. Treatment and prevention of recurrent labial herpes are targeted by specific antiviral agents. Spectacular benefits obtained in the immunocompromised patients are less convincing in otherwise healthy subjects. Other prospective ways of therapy are under consideration, including lipopeptides and physical means aiming at modifying the cutaneous pH. [less ▲]

Detailed reference viewed: 219 (4 ULg)
Peer Reviewed
See detailPharma clinics. Comment je traite ... un patient diabetique avec obesite severe.
Scheen, André ULg; Triches, K.; Luyckx, Françoise ULg et al

in Revue Médicale de Liège (1998), 53(7), 386-9

Obesity plays a crucial role in type 2 diabetes pathophysiology and a major weight loss markedly improves glycaemic control. The common failure of classical treatments leads to the use of more aggressive ... [more ▼]

Obesity plays a crucial role in type 2 diabetes pathophysiology and a major weight loss markedly improves glycaemic control. The common failure of classical treatments leads to the use of more aggressive weight-reduction approaches, such as very-low-calorie diets (VLCDs), anti-obesity drugs or even bariatric surgery. VLCDs are very successful in the short-term but rather disappointing in the long-term. Anti-obesity compounds only induce a modest mean weight reduction, even if some patients appear to be better responders. Interestingly, serotoninergic agents increase insulin sensitivity and glycaemic control, independently of weight loss. Bariatric surgery provides the most impressive results. In well-selected subjects, gastroplasty (either vertical ring gastroplasty or adjustable silicone gastric banding) generally induces a considerable weight loss which results in a remarkable and sustained glycaemic control improvement and allows the reduction, or even the suppression, of any antidiabetic treatment. This ultimate solution should not be neglected after failure of medical approaches, provided that the indication is correct, the surgical procedure is performed in a specialized centre and the followup is well organized by a multidisciplinary team. [less ▲]

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailPharma clinics. Comment je traite ... un trouble de la kaliémie
Neven, Ingrid; Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2000), 55(1), 4-7

The treatment of dyskalemia must be primarily etiological and later symptomatic. When moderate but significant hypokalemia exists (K < 3 mmol/l or 3.5 mmol/l with cardiac disease), oral K supplements must ... [more ▼]

The treatment of dyskalemia must be primarily etiological and later symptomatic. When moderate but significant hypokalemia exists (K < 3 mmol/l or 3.5 mmol/l with cardiac disease), oral K supplements must be given. The intravenous route must be reserved for emergency or impossible oral administration. Acute and severe hyperkalemia (K > 7 mmol/l) must be first corrected by different intravenous measures with secondary oral intervention. In chronic and/or moderate hyperkalemia (K > 5.5 mmol/l), the oral route for treatment is prefered. In any case, the research of the cause (mainly drug induced) is fundamental. [less ▲]

Detailed reference viewed: 180 (14 ULg)
Peer Reviewed
See detailPharma clinics. Comment je traite ... une anemie (3e partie).
Beguin, Yves ULg

in Revue Médicale de Liège (1995), 50(12), 497-8

Detailed reference viewed: 32 (6 ULg)
Peer Reviewed
See detailPharma clinics. Comment je traite.... Certaines maladies metaboliques grace a une intervention pharmacologique ciblee sur l'intestin.
Scheen, André ULg

in Revue Médicale de Liège (1998), 53(11), 646-50

Besides the classical dietary regimen, it is possible to use specific pharmacological approaches, targeted at the intestine, in order to treat some metabolic disorders. Three approaches will be described ... [more ▼]

Besides the classical dietary regimen, it is possible to use specific pharmacological approaches, targeted at the intestine, in order to treat some metabolic disorders. Three approaches will be described: anionic resins for treating hypercholesterolaemia, alpha-glucosidase inhibitors for treating diabetes mellitus and reactive hypoglycaemia, and intestinal lipase inhibitors for treating obesity. All these drugs are based on original concepts, but their clinical use is often limited by the occurrence of digestive side-effects. The latter may generally be reduced by progressive and individual titration of the dosage of each drug and/or by following an appropriate diet. [less ▲]

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailPharma clinics. Comment je traite.... L'arthrose. 1ère partie: Rappel physiopathologique et traitement symptomatique
Reginster, Jean-Yves ULg; Henrotin, Yves ULg

in Revue Médicale de Liège (2001), 56(2), 63-7

Osteoarthritis is now considered in all developed countries as a major burden for public health. During several years, the pharmacological management of osteoarthritis mainly focused on symptoms relief ... [more ▼]

Osteoarthritis is now considered in all developed countries as a major burden for public health. During several years, the pharmacological management of osteoarthritis mainly focused on symptoms relief without interaction with the long-term structural progression of this disease. Based on recently published consensus, the present article summarizes the currently available options in the symptom-modifying management of osteoarthritis. [less ▲]

Detailed reference viewed: 22 (2 ULg)
Full Text
Peer Reviewed
See detailPharma clinics. Comment je traite.... L'arthrose. 2eme partie: Nouvelles perspectives therapeutiques
Reginster, Jean-Yves ULg; Henrotin, Yves ULg

in Revue Médicale de Liège (2001), 56(3), 135-9

Besides the management of symptoms of osteoarthritis, a lot of interest was raised for molecules aiming at slowing down the structural progression of the disease. This paper summarizes the currently ... [more ▼]

Besides the management of symptoms of osteoarthritis, a lot of interest was raised for molecules aiming at slowing down the structural progression of the disease. This paper summarizes the currently available data allowing to discuss the efficacy and tolerance of these chemical entities. [less ▲]

Detailed reference viewed: 58 (3 ULg)
Full Text
Peer Reviewed
See detailPharma clinics. Le médicament du mois. L'imiquimod (Aldara): un immunomodulateur pour la peau.
Hermanns-Lê, Trinh ULg; Nikkels, Arjen ULg; Uhoda, Isabelle et al

in Revue Médicale de Liège (2002), 57(2), 116-8

Imiquimod is the first drug of a new therapeutic class encompassing cutaneous immune response modifiers. This molecule induces the synthesis and release of macrophage-related cytokines. It boosts some ... [more ▼]

Imiquimod is the first drug of a new therapeutic class encompassing cutaneous immune response modifiers. This molecule induces the synthesis and release of macrophage-related cytokines. It boosts some local immune responses. These properties are used to treat cutaneous viral condylomas. Other prospective therapeutic goals are presently scrutinized. [less ▲]

Detailed reference viewed: 110 (4 ULg)
Peer Reviewed
See detailPharma clinics. Le medicament du mois. La cerivastatine (Lipobay, Cholstat).
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(2), 117-20

Cerivastatin, commercialized under the trade names of Lipobay by Bayer and Cholstat by Fournier Pharma, is a new synthetic statin. Because of its high affinity for HMG-CoA reductase enzyme that it ... [more ▼]

Cerivastatin, commercialized under the trade names of Lipobay by Bayer and Cholstat by Fournier Pharma, is a new synthetic statin. Because of its high affinity for HMG-CoA reductase enzyme that it specifically and selectively inhibited in the hepatocytes, cerivastatin exerts its cholesterol-lowering effect at very low doses, between 0.1 and 0.3 mg/day. Cerivastatin is indicated, after diet failure, in the treatment of primary forms of isolated hypercholesterolaemia or combined hyperlipidaemia. It is presented by the two pharmaceutical companies as 0.1, 0.2 and 0.3 mg filmed tablets. Usual dose is 0.3 mg, once daily, to be reduced in presence of renal failure. Cerivastatin is metabolised within the liver by two different families of cytochrome P450, which limits the risk of drug interferences. Besides this potential advantage as compared with some other statins, its pharmacodynamic activity and safety profile seem to be similar to those of other agents of the same pharmacological family. [less ▲]

Detailed reference viewed: 33 (0 ULg)
Full Text
Peer Reviewed
See detailPharma clinics. Le médicament du mois. La lercanidipine (Zanidip)
Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (1999), 54(10), 832-834

Lercanidipine (Zanidip) is a new calcium antagonist belonging to the dihydropyridine family suitable for the first-line treatment of hypertension. This molecule displays a high specificity and selectivity ... [more ▼]

Lercanidipine (Zanidip) is a new calcium antagonist belonging to the dihydropyridine family suitable for the first-line treatment of hypertension. This molecule displays a high specificity and selectivity for vascular smooth muscle cells and has, in spite of a short plasma half-life, a long duration of action due to its liposolubility. The usual and once a day dose to treat high blood pressure of any grade is 10 mg, which if needed could be increased to 20 mg once a day. It has a gradual onset of effect on blood pressure, thus leading to a good tolerability and hopefully a better compliance in the treatment of hypertension. No adaptation of the dose is needed in older patients or in patients with moderate renal or liver impairment. [less ▲]

Detailed reference viewed: 236 (0 ULg)